Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Fibrogammin 250unit inj vials
0211000U0BBAAAA
|
Fibrogammin | Dried factor XIII fraction | Cardiovascular System | No data available |
|
Fibrovein 0.2% solution for injection 5ml vials
0213000T0BEABAH
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 1% solution for injection 2ml ampoules
0213000T0BEADAD
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 3% solution for injection 2ml ampoules
0213000T0BEAEAF
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 3% solution for injection 5ml vials
0213000T0BEAAAG
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Flecainide 100mg/5ml oral liquid
0203020I0AAAZAZ
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 10mg/5ml oral solution
0203020I0AABIBI
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 12.5mg/5ml oral liquid
0203020I0AABMBM
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 125mg/5ml oral liquid
0203020I0AABBBB
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 12mg/5ml oral liquid
0203020I0AAANAN
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 150mg/15ml solution for injection ampoules
0203020I0AAAAAA
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 15mg/5ml oral liquid
0203020I0AAASAS
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 17mg/5ml oral liquid
0203020I0AAATAT
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 18.75mg/5ml oral liquid
0203020I0AAAPAP
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 1mg/5ml oral liquid
0203020I0AABNBN
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 2.5mg/5ml oral liquid
0203020I0AAAYAY
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 200mg/5ml oral liquid
0203020I0AAAXAX
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 20mg/5ml oral liquid
0203020I0AAAWAW
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 250mg/5ml oral liquid
0203020I0AABLBL
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 30mg/5ml oral liquid
0203020I0AABABA
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 33.33mg/5ml oral liquid
0203020I0AAAUAU
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 35mg/5ml oral liquid
0203020I0AABKBK
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 37.5mg/5ml oral liquid
0203020I0AABHBH
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 40mg/5ml oral liquid
0203020I0AABCBC
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
|
Flecainide 4mg/5ml oral liquid
0203020I0AABPBP
|
Flecainide acetate | Flecainide acetate | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.